

A Multiplexed, Next Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2

3 Marie-Ming Aynaud^{1**}, J. Javier Hernandez^{1,3**}, Seda Barutcu^{1**}, Ulrich Braunschweig^{3,4},
4 Kin Chan¹, Joel D. Pearson¹, Daniel Trcka¹, Suzanna L. Prosser¹, Jaeyoun Kim¹, Miriam
5 Barrios-Rodiles¹, Mark Jen¹, Siyuan Song^{4,5}, Jess Shen¹, Christine Bruce², Bryn Hazlett²,
6 Susan Poutanen², Liliana Attisano^{4,5}, Rod Bremner¹, Benjamin J. Blencowe^{3,4}, Tony
7 Mazzulli², Hong Han^{3,4}, Laurence Pelletier^{1,3*}, Jeffrey L. Wrana^{1,3*}.

9 Supplementary information

10 **Supplementary Table 1: List of SARS-CoV-2 and human primers.** Primer sequences,
11 name of the targeted regions, size of amplicons after multiplex and barcode PCR are
12 indicated.

14 **Supplementary Table 2: Itemized cost of C19-SPAR-Sseq per sample**

16 **Supplementary Table 3: Description of the proof-of-concept cohort for C19-SPAR-**
17 **Seq detection of SARS-CoV-2.** Barcodes ID, sample identification (ID), date of retrieval,
18 collection method, diagnostic laboratory status, and 'BGI' qRT-PCR results are indicated.
19 These patient samples were used to develop C19-SPAR-Seq detection of SARS-CoV-2
20 (PoC cohort) (Fig. 1).

22 **Supplementary Table 4: Description of test development cohort.** Barcodes ID,
23 sample identification (ID), date of retrieval, collection method, diagnostic laboratory qRT-

24 PCR results ('Seegene') are indicated (n = 112). These patient samples were used to
25 establish SARS-CoV-2 clinical status assignment using diagnostic laboratory qRT-PCR
26 results ('Seegene') and to test C19-SPAR-Seq detection of SARS-CoV-2 (**Fig. 2,3**).
27

28 **Supplementary Table 5: Confusion matrix of the test development cohort.**

29
30 **Supplementary Table 6: Description of the pilot cohort.** Barcodes ID, sample
31 identification (ID), date of retrieval, collection method, diagnostic laboratory qRT-PCR
32 results ('Seegene'), 'BGI' qRT-PCR results are indicated. Filtered archival samples are
33 indicated. (Extended data **Fig. 3,4**).
34

35 **Supplementary Table 7: Description of the extended cohort.** Barcodes ID, sample
36 identification (ID), date of retrieval, collection method, diagnostic laboratory qRT-PCR
37 results ('Seegene'), and 'BGI' qRT-PCR results are indicated (**Fig. 4**).
38

39 **Supplementary Table 8: Confusion matrix of the extended cohort.**

40
41 **Supplementary Table 9: Group classifications**